24 May 2013
Keywords: Proximagen, Cash balance, Commercial and R&D highlights
Article | 05 March 2012
UK-based CNS and inflammatory diseases specialist Proximagen (AIM: PRX) has announced its unaudited preliminary annual results for the year ended ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 March 2012
6 March 2012
© 2013 thepharmaletter.com